Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Prasugrel Loading Dose Clear all
Completed Phase 2 Interventional Results available

Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

NCT00642174
View directory record Official record
Conditions
Diabetes Mellitus, Coronary Artery Disease
Interventions
prasugrel, Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Jacksonville, Florida • Worcester, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2010 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

NCT00357968
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel, Placebo for Prasugrel, Placebo for Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Jacksonville, Florida • Worcester, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2010 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)

NCT01510327
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Loveland, Colorado • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Not applicable Interventional Results available

Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease

NCT01852175
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 74 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Phase 4 Interventional Results available

Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease

NCT01587651
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel Loading Dose, Prasugrel Maintenance Dose, Ticagrelor Maintenance Dose
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 74 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Jacksonville, Florida • Miami, Florida • Port Orange, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)

NCT01597375
View directory record Official record
Conditions
Asthma, Aspirin-Induced, Aspirin Exacerbated Asthma
Interventions
Placebo Oral Tablet, Prasugrel Oral Tablet
Drug
Lead sponsor
Elliot Israel, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Phase 4 Interventional Results available

Prasugrel Re-load Strategies

NCT01201772
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 74 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 8, 2026, 8:03 AM EDT
Terminated Phase 4 Interventional Results available

Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)

NCT01612884
View directory record Official record
Conditions
Thrombosis, Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Phase 4 Interventional

The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel

NCT01365221
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Prasugrel
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Huntsville, Alabama • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

NCT00699998
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Clopidogrel, Prasugrel, Commercially-available Aspirin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
9,326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
165
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 162 more
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Phase 4 Interventional Results available

PROMUS Element Plus US Post-Approval Study

NCT01589978
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Plus Coronary Stent System, Aspirin, P2Y12 antagonist
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
2,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
52
States / cities
Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 8, 2026, 8:03 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Phase 4 Interventional Results available

Pharmacological Effects of Crushing Prasugrel in STEMI Patients

NCT02212028
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
prasugrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 27, 2016 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Phase 4 Interventional Results available

Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation

NCT01789814
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 8, 2026, 8:03 AM EDT
Not listed No phase listed Observational

African-American Pharmacogenetics

NCT01408121
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Not applicable Interventional Results available

Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes

NCT01852214
View directory record Official record
Conditions
Diabetes Mellitus, Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 74 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 8, 2026, 8:03 AM EDT
Not listed Not applicable Interventional

Plavix, Prasugrel and Drug Eluting Stents Pilot Trial

NCT01103843
View directory record Official record
Conditions
Coronary Artery Disease, Platelet Aggregation Inhibitors, PCI- Percutaneous Coronary Intervention
Interventions
Loading Dose Arm, Maintenance Dose Arm
Drug
Lead sponsor
St. Francis Hospital, New York
Other
Eligibility
21 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Not applicable Interventional Results available

Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor

NCT02016170
View directory record Official record
Conditions
Coronary Artery Disease, Acute Coronary Syndrome
Interventions
Ticagrelor 180mg, Prasugrel 10mg, Ticagrelor 90mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 74 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Phase 4 Interventional Results available

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

NCT03489863
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 8, 2026, 8:03 AM EDT
Terminated Phase 2 Interventional Results available

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

NCT03606642
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Stent Placement
Interventions
Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
Drug · Device
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
75 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

NCT00097591
View directory record Official record
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndromes
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
13,619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2010 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event

NCT00356135
View directory record Official record
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions
prasugrel 10 mg, clopidogrel, prasugrel placebo, prasugrel 60 mg, clopidogrel placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Jacksonville, Florida • Baltimore, Maryland • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Sep 8, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)

NCT00059215
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases
Interventions
Prasugrel (CS-747), Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2010 · Synced Sep 8, 2026, 8:03 AM EDT
Terminated Phase 2 Interventional Results available

Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)

NCT00910299
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Clearwater, Florida • Jacksonville, Florida • Rome, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Sep 8, 2026, 8:03 AM EDT